Cargando…

Early acquisition of [(18)F]FDOPA PET/CT imaging in patients with recurrent or residual medullary thyroid cancer is safe—and slightly better!

PURPOSE: The aim of this study was to compare early (15 min) and late (60 min) [(18)F]FDOPA PET/CT acquisition times in the detection of recurrence/residual disease in medullary thyroid cancer (MTC) patients. MATERIALS AND METHODS: Thirty-two dual-phase [(18)F]FDOPA PET scans were retrospectively re...

Descripción completa

Detalles Bibliográficos
Autores principales: Kjærulff, Mette Louise Gram, Dias, André H., Iversen, Peter, Gormsen, Lars Christian, Hjorthaug, Karin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402850/
https://www.ncbi.nlm.nih.gov/pubmed/36002696
http://dx.doi.org/10.1186/s41824-022-00140-7
_version_ 1784773240316493824
author Kjærulff, Mette Louise Gram
Dias, André H.
Iversen, Peter
Gormsen, Lars Christian
Hjorthaug, Karin
author_facet Kjærulff, Mette Louise Gram
Dias, André H.
Iversen, Peter
Gormsen, Lars Christian
Hjorthaug, Karin
author_sort Kjærulff, Mette Louise Gram
collection PubMed
description PURPOSE: The aim of this study was to compare early (15 min) and late (60 min) [(18)F]FDOPA PET/CT acquisition times in the detection of recurrence/residual disease in medullary thyroid cancer (MTC) patients. MATERIALS AND METHODS: Thirty-two dual-phase [(18)F]FDOPA PET scans were retrospectively reviewed. Scan indications were (1) suspected recurrence of MTC, (2) treatment monitoring, or (3) restaging. In four scans, no final verification could be obtained, and one scan was excluded due to non-consistency with the acquisition protocol. Images were analyzed visually and semiquantitatively (using SUV(max)). On both per-scan and per-lesion basis, early (median time 15 min) and late (median time 60 min) acquisition were compared by number and SUV(max) of detected MTC lesions, and a washout rate between the two acquisitions was calculated. Sensitivity and specificity of early and late acquisition were also compared. RESULTS: Out of the 27 eligible PET scans, twenty were classified as PET positive and 7 as PET negative. By subsequent histology and/or combination of imaging and clinical data during follow-up, the MTC diagnosis was verified, showing a scan-based sensitivity and specificity of 100% and 87.5%, respectively, for the early acquisition, and for the late acquisition both were 100%. However, there were no statistically significant difference in detection rate between the two acquisitions. Lesions on the early acquisition were significantly more intense compared to lesions on the late acquisition (median washout rate of − 33% (− 57 to + 50%)). CONCLUSION: Our study confirms that it is safe to omit the late [(18)F]FDOPA PET/CT acquisition in the detection of recurrent/residual MTC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41824-022-00140-7.
format Online
Article
Text
id pubmed-9402850
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-94028502022-08-26 Early acquisition of [(18)F]FDOPA PET/CT imaging in patients with recurrent or residual medullary thyroid cancer is safe—and slightly better! Kjærulff, Mette Louise Gram Dias, André H. Iversen, Peter Gormsen, Lars Christian Hjorthaug, Karin Eur J Hybrid Imaging Short Communication PURPOSE: The aim of this study was to compare early (15 min) and late (60 min) [(18)F]FDOPA PET/CT acquisition times in the detection of recurrence/residual disease in medullary thyroid cancer (MTC) patients. MATERIALS AND METHODS: Thirty-two dual-phase [(18)F]FDOPA PET scans were retrospectively reviewed. Scan indications were (1) suspected recurrence of MTC, (2) treatment monitoring, or (3) restaging. In four scans, no final verification could be obtained, and one scan was excluded due to non-consistency with the acquisition protocol. Images were analyzed visually and semiquantitatively (using SUV(max)). On both per-scan and per-lesion basis, early (median time 15 min) and late (median time 60 min) acquisition were compared by number and SUV(max) of detected MTC lesions, and a washout rate between the two acquisitions was calculated. Sensitivity and specificity of early and late acquisition were also compared. RESULTS: Out of the 27 eligible PET scans, twenty were classified as PET positive and 7 as PET negative. By subsequent histology and/or combination of imaging and clinical data during follow-up, the MTC diagnosis was verified, showing a scan-based sensitivity and specificity of 100% and 87.5%, respectively, for the early acquisition, and for the late acquisition both were 100%. However, there were no statistically significant difference in detection rate between the two acquisitions. Lesions on the early acquisition were significantly more intense compared to lesions on the late acquisition (median washout rate of − 33% (− 57 to + 50%)). CONCLUSION: Our study confirms that it is safe to omit the late [(18)F]FDOPA PET/CT acquisition in the detection of recurrent/residual MTC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41824-022-00140-7. Springer International Publishing 2022-08-25 /pmc/articles/PMC9402850/ /pubmed/36002696 http://dx.doi.org/10.1186/s41824-022-00140-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Short Communication
Kjærulff, Mette Louise Gram
Dias, André H.
Iversen, Peter
Gormsen, Lars Christian
Hjorthaug, Karin
Early acquisition of [(18)F]FDOPA PET/CT imaging in patients with recurrent or residual medullary thyroid cancer is safe—and slightly better!
title Early acquisition of [(18)F]FDOPA PET/CT imaging in patients with recurrent or residual medullary thyroid cancer is safe—and slightly better!
title_full Early acquisition of [(18)F]FDOPA PET/CT imaging in patients with recurrent or residual medullary thyroid cancer is safe—and slightly better!
title_fullStr Early acquisition of [(18)F]FDOPA PET/CT imaging in patients with recurrent or residual medullary thyroid cancer is safe—and slightly better!
title_full_unstemmed Early acquisition of [(18)F]FDOPA PET/CT imaging in patients with recurrent or residual medullary thyroid cancer is safe—and slightly better!
title_short Early acquisition of [(18)F]FDOPA PET/CT imaging in patients with recurrent or residual medullary thyroid cancer is safe—and slightly better!
title_sort early acquisition of [(18)f]fdopa pet/ct imaging in patients with recurrent or residual medullary thyroid cancer is safe—and slightly better!
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402850/
https://www.ncbi.nlm.nih.gov/pubmed/36002696
http://dx.doi.org/10.1186/s41824-022-00140-7
work_keys_str_mv AT kjærulffmettelouisegram earlyacquisitionof18ffdopapetctimaginginpatientswithrecurrentorresidualmedullarythyroidcancerissafeandslightlybetter
AT diasandreh earlyacquisitionof18ffdopapetctimaginginpatientswithrecurrentorresidualmedullarythyroidcancerissafeandslightlybetter
AT iversenpeter earlyacquisitionof18ffdopapetctimaginginpatientswithrecurrentorresidualmedullarythyroidcancerissafeandslightlybetter
AT gormsenlarschristian earlyacquisitionof18ffdopapetctimaginginpatientswithrecurrentorresidualmedullarythyroidcancerissafeandslightlybetter
AT hjorthaugkarin earlyacquisitionof18ffdopapetctimaginginpatientswithrecurrentorresidualmedullarythyroidcancerissafeandslightlybetter